Scarica l'app Stockscreener
65.14
0.65%
0.42
Dopo l'orario di chiusura:
65.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharma CEO Peetz sells $2.48 million in shares By Investing.com - Investing.com Canada
Mirum Pharma CFO Eric Bjerkholt sells $524k in stock By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $89.00 at Evercore ISI - MarketBeat
Mirum Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingReal Trader Watchlist of Hot Stocks Released - 선데이타임즈
Is Mirum Pharmaceuticals Inc. forming bullish engulfing patternsBest 5x Return Trade Entries - thegnnews.com
Stifel Initiates Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Announces Target Price $89 - 富途牛牛
Mirum's Meteoric Surge: What's Fueling the 9.38% Intraday Rally? - AInvest
HC Wainwright Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
Mirum’s Financial Rocket: Soaring Figures, Intriguing Questions - StocksToTrade
Mirum Soars 10% on Analyst Upgrades and Pipeline Catalysts: Is This the Start of a Biotech Breakout? - AInvest
Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates - simplywall.st
Mirum Pharmaceuticals: Q2 Results Continues To Show Positive Momentum (NASDAQ:MIRM) - Seeking Alpha
Stifel resumes Mirum Pharmaceuticals stock coverage with Buy rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Delivers Growth With Orphan Liver Drug Success - Finimize
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2025 Earnings Call Transcript - MSN
Insider Selling at Mirum Pharmaceuticals: A Signal of Confidence or Caution for Long-Term Investors? - AInvest
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $66 to $89 - 富途牛牛
BioLife Solutions: HC Wainwright Raises PT to $32, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James - TipRanks
Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance - TipRanks
Mirum Pharmaceuticals Raises Revenue Guidance, Secures Reimbursement in Japan, and Expands Product Portfolio - AInvest
Citizens JMP Raises Mirum Pharmaceuticals Price Target to $81, Maintains Outperform Rating - AInvest
MIRM Stock Flying High: Too Late to Buy? - StocksToTrade
Mirum Pharmaceuticals shares rise 12.83% intraday after reporting strong Q2 results and raising 2025 guidance. - AInvest
MIRM Stock Up On Q2 Earnings And Revenue Beat, Raised 2025 View - Barchart.com
Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP - TipRanks
Mirum Soars 10.5% on Earnings Beat and Revenue Surge: A Biotech Breakout in the Making? - AInvest
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD - Investing.com
Mirum: JMP Securities Raises PT to $81, Maintains Market Outperform - AInvest
Mirum:Raymond James raises PT to $82, maintains Strong Buy rating. - AInvest
Mirum Pharmaceuticals stock price target raised to $80 from $73 at H.C. Wainwright - Investing.com Canada
Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright - TipRanks
Mirum:HC Wainwright Raises PT to $80, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals stock price target raised to $81 by JMP - Investing.com South Africa
Mirum 2025 Q2 Earnings Losses Narrow Significantly - AInvest
Earnings call transcript: Mirum Pharmaceuticals sees revenue boost in Q2 2025 - Investing.com
Mirum Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Mirum Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Mirum Pharmaceuticals Q2 2025: Unpacking Contradictions on Market Penetration, Sales Growth, and Clinical Strategy - AInvest
Mirum Pharmaceuticals Reports Q2 2025 Earnings and Business Update - AInvest
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals soars as revenue crushes estimates - Investing.com
Mirum Pharmaceuticals earnings beat by $0.21, revenue topped estimates - Investing.com Canada
Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c) - TipRanks
Earnings Flash (MIRM) Mirum Pharmaceuticals, Inc. Reports Q2 Revenue $127.8M, vs. FactSet Est of $108.1M - MarketScreener
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
Mirum Pharmaceuticals Q2 2025 Earnings Preview: EPS Estimate $-0.33, Revenue Estimate $108.1M. - AInvest
Traders Consider Averaging Down in Mirum Pharmaceuticals Inc.Community Verified Stock Suggestions Drive Volume - metal.it
Is Mirum Pharmaceuticals Inc. a growth stock or a value stockStay informed with expert market forecasts - Jammu Links News
How does Mirum Pharmaceuticals Inc. compare to its industry peersDiscover high-impact investment opportunities - Jammu Links News
What catalysts could drive Mirum Pharmaceuticals Inc. stock higher in 2025Unstoppable trading performance - Jammu Links News
Why is Mirum Pharmaceuticals Inc. stock attracting strong analyst attentionNavigate the market with precision tools - Jammu Links News
How many analysts rate Mirum Pharmaceuticals Inc. as a “Buy”Market-crushing profits - Jammu Links News
Should I hold or sell Mirum Pharmaceuticals Inc. stock in 2025Achieve rapid financial growth with smart picks - jammulinksnews.com
Is Mirum Pharmaceuticals Inc. stock overvalued or undervaluedRapid market gains - Jammu Links News
How does Mirum Pharmaceuticals Inc. generate profit in a changing economyMaximize returns with disciplined trading - Jammu Links News
How volatile is Mirum Pharmaceuticals Inc. stock compared to the marketHigh-profit trading signals - Jammu Links News
What analysts say about Mirum Pharmaceuticals Inc. stockUnmatched market performance - Jammu Links News
What are the latest earnings results for Mirum Pharmaceuticals Inc.Get ahead with breakthrough trading ideas - Jammu Links News
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):